Ann: Notice of Investor Call and Presentation, page-34

There are two formulations of Exenatide on the market for Type 2 Diabetes. There is a short acting 'Byetta' that works for 12 hours, and a long acting 'Bydureon' that works for 7 days.

Invex has been reformulating Exenatide to last for 24 hours around the disease profile and named it 'Presendin'.

Today, Invex has given up and decided to use Peptron's reformulation for sustained release Exenatide instead.

A year ago, in March 2020, Invex's Investor presentation referred to their daily presendin reformulation as being ideal and claimed that the Bydureon's 3 hour time of onset was too slow.

But today, they've flipped and decided it's easier to just use Peptron's reformulated exenatide and accept the three hour time of onset that it has.

This slide and the backflip today has made me re-examine my investment thesis.